Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer

Tang, Baolan; Yao, Peng; Yue, Qiming; Pu, Yanchi; Li, Ru; Zhao, Yi; Li, Hai; Guo, Li; Wu, Yong

doi:10.1016/j.ejmech.2020.112204

Cited by 49 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to cancer therapy, liposomes provide a good platform for in vivo delivery of many anti-tumor drugs, such as doxorubicin and paclitaxel, among other chemotherapeutic agents, as well as nucleic acids (Chen et al, 2010;Wang X. et al, 2017). In the field of breast and prostate cancer (Yari et al, 2019), the application of liposomes has been increasingly common (Satsangi et al, 2015;Tang B. et al, 2020). Multiple paclitaxel liposomes have been demonstrated to have higher anti-tumor efficiency and improved bioavailability compared to free paclitaxel (Han et al, 2020).…”

Section: Organic Npsmentioning

confidence: 99%

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yao

Zhou

Liu

et al. 2020

Front. Mol. Biosci.

812

346

View full text Add to dashboard Cite

Nanotechnology has been extensively studied and exploited for cancer treatment as nanoparticles can play a significant role as a drug delivery system. Compared to conventional drugs, nanoparticle-based drug delivery has specific advantages, such as improved stability and biocompatibility, enhanced permeability and retention effect, and precise targeting. The application and development of hybrid nanoparticles, which incorporates the combined properties of different nanoparticles, has led this type of drug-carrier system to the next level. In addition, nanoparticle-based drug delivery systems have been shown to play a role in overcoming cancer-related drug resistance. The mechanisms of cancer drug resistance include overexpression of drug efflux transporters, defective apoptotic pathways, and hypoxic environment. Nanoparticles targeting these mechanisms can lead to an improvement in the reversal of multidrug resistance. Furthermore, as more tumor drug resistance mechanisms are revealed, nanoparticles are increasingly being developed to target these mechanisms. Moreover, scientists have recently started to investigate the role of nanoparticles in immunotherapy, which plays a more important role in cancer treatment. In this review, we discuss the roles of nanoparticles and hybrid nanoparticles for drug delivery in chemotherapy, targeted therapy, and immunotherapy and describe the targeting mechanism of nanoparticle-based drug delivery as well as its function on reversing drug resistance.

show abstract

Section: Organic Npsmentioning

confidence: 99%

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yao

Zhou

Liu

et al. 2020

Front. Mol. Biosci.

812

346

View full text Add to dashboard Cite

show abstract

“…Liposomes have biocompatible and biodegradable properties and most acceptable as drug delivery vehicles. These nanocarriers can move through lipid bilayers of cancer cells with increased AZA concentration at the site of action and eventually increase cytotoxicity [13,14]. To the best of the authors' knowledge, to date, AZA-loaded liposomes were not formulated.…”

Section: Introductionmentioning

confidence: 99%

QbD Enabled Azacitidine Loaded Liposomal Nanoformulation and Its In Vitro Evaluation

et al. 2021

View full text Add to dashboard Cite

Azacitidine (AZA), an inhibitor of DNA methyltransferase, is a commonly recognized drug used in clinical treatment for myelodysplastic syndrome and breast cancer. Due to higher aqueous solubility and negative log P of AZA causes poor cancer cell permeation and controlled release. The objective of the present study was to formulate and optimize AZA-loaded liposome (AZA-LIPO) for breast cancer chemotherapy by using Box Behnken design (BBD) and in vitro evaluation using MCF-7 cells. AZA-LIPO were prepared using a thin film hydration technique and characterization study was performed by using FTIR and DSC. The prepared formulations were optimized using BBD and the optimized formulation was further subjected for particle size, surface charges, polydispersity index (PDI), drug loading, entrapment efficiency, TEM, XRD, in-vitro drug release and hemolytic toxicity. The mean particle size of optimized AZA-LIPO was 127 nm. Entrapment efficiency and drug loading of AZA-LIPO was found to be 85.2% ± 0.5 and 6.82 ± 1.6%, respectively. Further, in vitro drug release study showed preliminary burst release in 2 h followed by a sustained release for 36 h in phosphate buffer at different pH (4.0, 5.5, and 7.4) as compared to free drug. Drug release was found to be pH dependent, as the pH was increased, the drug release rate was found to be low. Time-dependent cell viability assay exhibited significant higher cell viability and higher internalization than free AZA in MCF-7 cells. AZA-LIPO were more effective than the free AZA in reducing Bcl2 expression, while increasing pro-apoptotic Bax and caspase-3 activity. The result showed that the formulated biocompatible AZA-LIPO nano-formulations may be used as an efficient anti-cancer drug delivery system for the treatment of breast cancer after establishing preclinical and clinical studies.

show abstract

“…Therefore, a novel micellar delivery system composed of poly(lactide)‐co‐poly(ethylene glycol)‐biotin (PLA–PEG‐BIO) was used for co‐administration of these two drugs. It is believed that micelles modified with target‐specific ligand (BIO) may enhance anticancer activity and reduce toxicity to normal cells due to increased uptake by biotin receptor‐mediated endocytosis 14 . We expect that EpoB/Rap‐loaded PLA–PEG‐BIO micelles can be used for the treatment of breast cancer with a milder phenotype or even TNBC.…”

Section: Introductionmentioning

confidence: 99%

Cytotoxic effect of targeted biodegradable epothilone B and rapamycin co‐loaded nanocarriers on breast cancer cells

Zajdel

Wilczok

Jelonek

et al. 2021

J Biomedical Materials Res

View full text Add to dashboard Cite

The new therapeutic solutions for breast cancer treatment are needed, for example, combined therapy consisted of several drugs that characterize different mechanisms of action and modern drug delivery systems. Therefore, we used combination of epothilone B (EpoB) and rapamycin (Rap) to analyze the cytotoxic effect against breast cancer cells (MCF‐7; MDA‐MB‐231). Also, the effect of drugs co‐delivered in bioresorbable micelles functionalized with biotin (PLA–PEG‐BIO; poly(lactide)‐co‐poly(ethylene glycol)‐biotin) was studied. The comparison of effects of the mixture of free drugs and the micelles co‐loaded with EpoB and Rap revealed a significant decrease in the cell metabolic activity and survival. Moreover, the dual drug‐loaded PLA–PEG‐BIO micelles enhanced the cytotoxicity of EpoB and Rap against the tested cells as compared with the free drugs. The blank PLA–PEG‐BIO micelles did not affect the tested cells. We expect that mixture of EpoB and Rap may be promising in breast cancer treatment and PLA–PEG‐BIO micelles as carrier of these two drugs can be applicable for successful targeted delivery.

show abstract

Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer

Cited by 49 publications

References 42 publications

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

QbD Enabled Azacitidine Loaded Liposomal Nanoformulation and Its In Vitro Evaluation

Cytotoxic effect of targeted biodegradable epothilone B and rapamycin co‐loaded nanocarriers on breast cancer cells

Contact Info

Product

Resources

About